Figure 1From: Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation Anti-HBs levels during treatment with HIP versus commercial HBIG. Pooled anti-HBs levels from all 21 patients during treatment with HIP and anti-HBs levels in 8 patients when they were switched to commercial HBIGBack to article page